文献速递烧伤创面修复

菠萝蛋白酶酶解清创的意大利全国烧伤数据库临床结局分析

Clinical outcomes of bromelain-based enzymatic debridement (NexoBrid®): evidence from the Italian National Burn Database.
PubMed 文献 · Burns · 2026-02-16

基于意大利国家烧伤数据库2238例完整核心数据患者的回顾性研究,评估菠萝蛋白酶酶解清创(NexoBrid®)与生存、焦痂切开、植皮、手术次数及住院时长(LOS)的关联。结果显示酶解清创不增加死亡风险,独立降低焦痂切开需求(OR 0.47,p < 0.001),但植皮可能性和手术次数更高,LOS无显著差异。

要点

  • 酶解清创不增加死亡风险,真实世界安全性获证实
  • 酶解清创独立降低焦痂切开需求(OR 0.47,p < 0.001)
  • 酶解清创患者植皮可能性及手术次数更高,LOS无显著差异

核心结论

  • 菠萝蛋白酶酶解清创在真实世界实践中安全,不增加死亡风险。
  • 酶解清创独立降低焦痂切开需求,但可能增加植皮和手术次数。
  • 两组住院时长无显著差异,酶解清创在特定患者中仍有价值。

研究设计与样本

  • 回顾性研究,分析意大利国家烧伤数据库2018至2024年2238例完整核心数据患者。
  • 对每个结局构建多变量回归模型,调整年龄、烧伤面积和吸入性损伤等协变量。

主要发现

  • 酶解清创与标准手术治疗相比未对生存产生负面影响。
  • 酶解清创独立关联焦痂切开需求显著降低(OR 0.47,p < 0.001)。
  • NexoBrid®治疗患者植皮可能性更高且总体手术次数更多。
  • 两组住院时长(LOS)无显著差异。

关键数值与推荐

  • 焦痂切开需求:OR 0.47,p < 0.001,支持酶解清创在环形烧伤中避免减压性焦痂切开的作用。
  • 生存、植皮、手术次数和LOS为评估的主要结局,多变量模型调整年龄、烧伤面积和吸入性损伤。

临床怎么用

  • 酶解清创可用于环形烧伤以减少焦痂切开需求,但需预期后续植皮和手术次数可能增加。
  • 在选定患者中酶解清创可作为传统手术切除的替代方案,需权衡手术工作量。

局限性

  • 回顾性研究设计,需进一步前瞻性研究明确长期功能和资源影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: NexoBrid® (bromelain-based enzymatic debridement) has emerged as an alternative to traditional surgical excision in burn management, yet its overall impact on clinical outcomes in large unselected populations remains under discussion. METHODS: This retrospective study analyzed data from the Italian National Burn Database, including 2238 patients with complete core data treated between 2018 and 2024, to assess the association between NexoBrid® use and major outcomes: survival, escharotomy, skin grafting, number of surgical procedures, and hospital length of stay (LOS). Multivariable regression models were built for each outcome, adjusting for key covariates such as age, burn extent, and inhalation injury. RESULTS: Enzymatic debridement did not negatively affect survival compared to standard surgical treatment, confirming its safety in real-world clinical practice. Importantly, enzymatic debridement was independently associated with a significant reduction in the need for escharotomy (OR 0.47, p < 0.001), reinforcing its established role in managing circumferential burns without decompressive escharotomies. Conversely, NexoBrid®-treated patients showed a higher likelihood of undergoing skin grafting and required more procedures overall, potentially reflecting the need for planned reconstructive care following enzymatic eschar removal. No significant differences were observed in LOS between the two treatment groups. CONCLUSION: These findings confirm the safety of NexoBrid® and its potential procedural benefits, particularly in reducing the invasiveness of early surgical management. While enzymatic debridement may increase surgical workload due to planned grafting, it remains a valuable tool in selected patients. Further prospective research is needed to clarify its long-term functional and resource-related impact, but its role in modern burn care appears increasingly consolidated.

来源:Burns,查看原文。版权归原作者所有。

引用

  1. Marchica P, Ranno R, D'Alessio R, et al. Clinical outcomes of bromelain-based enzymatic debridement (NexoBrid®): evidence from the Italian National Burn Database. Burns. 2026. PMID: 41707536. doi:10.1016/j.burns.2026.107915

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。